SiRNA targeting stathmin inhibits invasion and enhances chemotherapy sensitivity of stem cells derived from Glioma cell lines

Acta Biochimica et Biophysica Sinica

Volumn 46, Issue 12, 2014, Pages 1034-1040

  Song, Yuwen ^a   Mu, Luyan ^a   Han, Xuezhe ^b   Liu, Xiaoqian ^a   Fu, Songbin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Glioma stem cells; Invasion; Stathmin; Temozolomide

Indexed keywords

ANTINEOPLASTIC AGENT; PRIMER DNA; SMALL INTERFERING RNA; STATHMIN;

BRAIN NEOPLASMS; CANCER STEM CELL; DRUG EFFECTS; GENE SILENCING; GENETICS; GLIOMA; HUMAN; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BRAIN NEOPLASMS; CELL LINE, TUMOR; DNA PRIMERS; GENE SILENCING; GLIOMA; HUMANS; NEOPLASTIC STEM CELLS; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; STATHMIN;

EID: 84929161889     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmu099     Document Type: Article

References (30)

1. Shrieve DC, Alexander E, 3rd, Black PM, Wen PY, Fine HA, Kooy HM and Loeffler JS. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 1999, 90:72-77.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A and Scheithauer BW, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
3. Charalambous C, Chen TC and Hofman FM. Characteristics of tumorassociated endothelial cells derived from glioblastoma multiforme. Neurosurg Focus 2006, 20:E22.
4. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks PB. Identification of a caner stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
5. Dietrich J, Diamond EL and Kesari S. Glioma stem cell signaling: therapeutic opportunities and challenges. Expert Rev Anticancer Ther 2010, 10:709-722.
6. O'Brien CA, Kreso A and Jamieson CH. Cancer stem cells and selfrenewal. Clin Cancer Res 2010, 16:3113-3120.
7. Yue WY and Chen ZP. Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem 2005, 53:997-1002.
8. El Hallani S, Boisselier B, Peglion F, Rousseau A, Colin C, Idbaih A and Marie Y, et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 2010, 133:973-982.
9. Liu XM, Zhang QP, Mu YG, Zhang XH, Sai K, Pang JC and Nq HK, et al. Clinical significance of vasculogenic mimicry in human gliomas. J Neurooncol 2011, 105:173-179.
10. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J and Trent JM, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999, 155:739-752.
11. Sun B, Qie S, Zhang S, Sun T, Zhao X, Gao S and Ni C, et al. Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum Pathol 2008, 39:444-451.
12. Liu Z, Li Y, Zhao W, Ma Y and Yang X. Demonstration of vasculogenic mimicry in astrocytomas and effects of endostar on U251 cells. Pathol Res Pract 2011, 207:645-651.
13. Chen Y, Jing Z, Luo C, Zhuang M, Xia J, Chen Z and Wang Y. Vasculogenic mimicry-potential target for glioma therapy: an in vitro and in vivo study. Med Oncol 2012, 29:324-331.
14. Ping YF and Bian XW. Consise review: contribution of cancer stem cells to neovascularization. Stem cells 2011, 29:888-894.
15. Bhat KM and Setaluri V. Microtube-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 2007, 13:2849-2854.
16. Dong B, Mu L, Qin X, Qiao W, Liu X, Yang L and Xue L, et al. Stathmin expression in glioma-derived microvascular endothelial cells: a novel therapeutic target. Oncol Rep 2012, 3:714-718.
17. Leibl S, Zigeuner R, Hutterer G, Chromecki T, Rehak P and Langner C. EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology. APMIS 2008, 116:27-32.
18. Cassimeris L. The oncoprotein 18/Stathmin family of microtubule destabilizers. Curr Opin Cell Biol 2002, 14:18-24.
19. Rana S, Maples PB, Senzer N and Nemunaitis J. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 2008, 8:1461-1470.
20. Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ and Lin CY, et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 2006, 209:549-558.
21. Ghosh R, Gu G, Tillman E, Yuan J, Wang Y, Fazli L and Rennie PS, et al. Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. Prostate 2007, 67:1038-1052.
22. Wang R, Dong K, Lin F, Wang X, Gao P, Wei SH and Cheng SY, et al. Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated down regulation of stathmin expression. Mol Med 2007, 13:567-575.
23. Alli E, Yang JM and Hait WN. Silencing of stathmin induces tumorsuppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2007, 26:1003-1012.
24. 6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006, 96:766-776.
25. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y and Konodo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004, 11:448-457.
26. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT and Brock C. Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Treat Rev 1997, 23:35-61.
27. Tran B and Rosenthal MA. Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 2010, 17:417-421.
28. Castedo M, Perfettini JL, Roumier T, Yskushijin K, Horne D, Medema R and Kroemer G. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 2004, 23:4353-4361.
29. Folberg R and Maniotis AJ. Vasculogenic mimicry. APMIS 2004, 112:508-525.
30. Yan GN, Lv YF, Yang L, Yao XH, Cui YH and Guo DY. Glioma stem cells enhance endothelial cell migration and proliferation via the Hedgehog pathway. Oncol Lett 2013, 6:1524-1530.